Art

J-GLOBAL ID：201402226739203465   Reference number：14A0907206

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

化学療法の繰り返しサイクルの間における化学療法誘発悪心および嘔吐の予防のためのネツピタントとパロノセトロンの固定用量併用NEPAの有効性と安全性を評価する第III相試験

Author (8)： GRALLA R. J. (Albert Einstein Coll. Medicine, Bronx, USA) ,  BOSNJAK S. M. (Inst. Oncology and Radiology of Serbia, Belgrade, ZZZ) ,  HONTSA A. (Chernivtsi Regional Cancer Hospital, Chernivtsi, UKR) ,  BALSER C. (OnkoNet Marburg GmbH, Marburg, DEU) ,  RIZZI G. (Helsinn Healthcare SA, Lugano, CHE) ,  ROSSI G. (Helsinn Healthcare SA, Lugano, CHE) ,  BORRONI M. E. (Helsinn Healthcare SA, Lugano, CHE) ,  JORDAN K. (Univ. Halle-Wittenburg, Halle, DEU)
Material： Annals of Oncology  (Ann Oncol)
Volume： 25  Issue： 7  Page： 1333-1339  Publication year： Jul. 2014 
JST Material Number： W0107A  ISSN： 0923-7534  CODEN： ANONE2  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： NK1 receptor antagonist ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A0907206&from=J-GLOBAL&jstjournalNo=W0107A") }}

JST classification (2)： Clinical application of drugs acting on digestive system  (GW09020B) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (3)： Netupitant ,  Dexamethasone ,  Palonosetron

Reference (7)：

• De Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003; 22: 4105-4111.
• De Wit R, Schmitz PIM, Verweij J et al. Analysis of cumulative probabilities shows that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J Clin Oncol 1996; 14: 644-651.
• Rojas C, Slusher BS. Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 2012; 684(1-3): 1-7.
• Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 2011; 22(1): 30-38.
• Hesketh P, Rossi G, Rizzi G et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25: 1340-1346.

Terms in the title (14)： 化学療法 ,  サイクル ,  誘発 ,  悪心 ,  嘔吐 ,  予防 ,  ネツピタント ,  パロノセトロン ,  用量 ,  併用 ,  有効性 ,  安全性 ,  評価 ,  第III相試験